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No Evidence that Knops Blood 
Group Polymorphisms Affect 
Complement Receptor 1 Clustering 
on Erythrocytes
O. V. Swann1, E. M. Harrison2, D. H. Opi1,3,5, E. Nyatichi3, A. Macharia3, S. Uyoga3, 
 T. N. Williams3,4 & J. A. Rowe  1
Clustering of Complement Receptor 1 (CR1) in the erythrocyte membrane is important for immune-
complex transfer and clearance. CR1 contains the Knops blood group antigens, including the 
antithetical pairs Swain-Langley 1 and 2 (Sl1 and Sl2) and McCoy a and b (McCa and McCb), whose 
functional effects are unknown. We tested the hypothesis that the Sl and McC polymorphisms might 
influence CR1 clustering on erythrocyte membranes. Blood samples from 125 healthy Kenyan children 
were analysed by immunofluorescence and confocal microscopy to determine CR1 cluster number and 
volume. In agreement with previous reports, CR1 cluster number and volume were positively associated 
with CR1 copy number (mean number of CR1 molecules per erythrocyte). Individuals with the McCb/
McCb genotype had more clusters per cell than McCa/McCa individuals. However, this association was 
lost when the strong effect of CR1 copy number was included in the model. No association was observed 
between Sl genotype, sickle cell genotype, α+thalassaemia genotype, gender or age and CR1 cluster 
number or volume. Therefore, after correction for CR1 copy number, the Sl and McCoy polymorphisms 
did not influence erythrocyte CR1 clustering, and the effects of the Knops polymorphisms on CR1 
function remains unknown.
Complement receptor 1 (CR1) is a polymorphic transmembrane glycoprotein expressed in humans on eryth-
rocytes, most leucocytes and glomerular podocytes1. It is encoded by the CR1 gene at the 1q32 locus, spanning 
approximately 133 kb and consisting of 39 exons2. Four size polymorphisms of CR1 have been identified, the 
most common form being CR1*13. This classical form has a molecular weight of 190 kDa under non-reducing 
conditions, with an ectodomain comprising 30 short consensus repeats (SCRs), the first 28 of which are arranged 
into four long homologous repeats (LHRs) A-D (Fig. 1)4. Insertion or deletion of LHRs accounts for the varia-
tion seen in the molecule size4. Variation also occurs in erythrocyte CR1 copy number, with the mean number 
of CR1 molecules per cell varying between individuals from 50 to 12005. A HindIII restriction fragment length 
polymorphism in intron 27 of the CR1 gene correlates with high (H allele) or low (L allele) CR1 expression on 
erythrocytes6. However, this polymorphism is not associated with CR1 copy number in African populations7,8.
CR1 is a key regulator of complement cascade activation, namely through accelerating the decay of C3 and C5 
convertases thus reducing production of anaphylotoxins C3a and C5a9, and acting as a cofactor with Factor I to 
inactivate C3b and C4b to iC3b and iC4b10. These functions map to specific sites within the CR1 molecule, with 
site 1 (SCRs 1–3 in LHR-A) displaying high decay accelerating activity11 and binding C4b12,13, and site 2 (SCRs 
8–10 in LHR B and SCRs 15–17 in LHR C) being responsible for cofactor activity with Factor I and the binding 
of C3b and C4b (Fig. 1)12,13.
The function of the LHR-D region of CR1 is unclear, but may include binding sites for C1q14 and Mannose 
Binding Lectin (MBL)15. SCR 25 in LHR-D also contains the Knops blood group antigens, which include the 
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Swain-Langley (antithetical pairs Sl1 and Sl2) and McCoy (McCa and McCb) antigens (Fig. 1)16. The Sl2 allele 
results from a single nucleotide polymorphism (SNP) (rs17047661), encoding an amino acid change from argi-
nine to glycine (R1601G), while the McCb allele results from a SNP 33 base pairs away (rs17047660), encoding 
an amino acid change from lysine to glutamic acid (K1590E) (Fig. 1)16. The functional effects of the Sl2 and McCb 
polymorphisms remain unknown. Recent work investigating short recombinant proteins bearing the Sl and McC 
antigens found no difference between the variant forms in their affinities for immobilised C3b, C4b or C1q, nor 
in their co-factor activity for cleavage of C3b and C4b in conjunction with Factor I17.
A marked geographical difference is seen in the frequency of Sl2 and McCb alleles, with the alleles being 
common in African populations and rare in Caucasians18. This has led to the suggestion that these polymor-
phisms arose due to selection pressure from malaria19, however, studies to date have been conflicting. An obser-
vational study from Western Kenya reported an association between the Sl2/Sl2 genotype and a reduced odds 
ratio of cerebral malaria (OR 0.17, p = 0.02) when compared to the Sl1/Sl1 genotype20. Recently, analysis of a 
large case-control study from Kilifi (eastern Kenya) identified an association between the Sl2/Sl2 genotype and 
protection against cerebral malaria and death from malaria, but conversely found addition of the McCb allele to 
be associated with increased odds of cerebral malaria (Opi, Swann et al., submitted). However, studies from The 
Gambia and Ghana did not find significant associations between the polymorphisms and severe malaria21,22.
In addition to complement regulation, CR1 on erythrocytes is responsible for immune adherence, the binding 
and transfer of opsonised immune complexes (ICs) from the circulation to resident macrophages in the liver 
and spleen for phagocytosis23,24. The clustering of CR1 in the erythrocyte membrane is thought to play a key 
role in its immune adherence function. On the resting erythrocyte membrane, CR1 is widely dispersed in small 
clusters, which coalesce into larger clusters when cross-linked by ligands or antibodies25–31. CR1 has also been 
demonstrated to co-immunoprecipitate with Fas-associated binding protein 1 (FAP-1) in the cytoskeleton frac-
tion, which acts as a scaffolding protein for cross-linked CR1 and cluster formation28. It has been hypothesized 
that CR1 clustering after cross-linking by ligands could prevent ingestion of the erythrocyte during IC transfer to 
macrophages by concentrating opsonic stimuli in a few areas of the membrane28. Ligation of CR1 has also been 
demonstrated to increase erythrocyte deformability, which could allow IC-laden erythrocytes to traverse the 
hepatic and splenic capillaries and transfer their cargo to the resident macrophages more easily29.
The number of CR1 clusters per erythrocyte increases with CR1 copy number25,32,33, although CR1 copy num-
ber alone does not completely explain inter-individual variation in clustering, implying involvement of other 
factors32. The possibility that the Sl2 polymorphism might affect CR1 clustering has been raised34, but never 
investigated. If the Knops blood group is indeed associated with malaria, there are a number of mechanistic 
possibilities that could include a role for variation in CR1 clustering. If the Sl2 or McCb mutations influenced the 
size or number of CR1 clusters formed, this might influence the process of invasion of Plasmodium falciparum 
into the erythrocyte via CR1 “capping” of the merozoite35. Alternatively, CR1 clustering could be important in the 
pathogenesis of cerebral malaria. Children with cerebral malaria may have higher circulating levels of immune 
complexes (ICs) than children with other malaria disease syndromes36. ICs deposited on the endothelial surface 
can activate complement and stimulate the release of local pro-inflammatory mediators37. ICs can also cross-link 
Fc-receptors on monocyte and macrophages, stimulating production of tumour necrosis factor38, a cytokine 
whose relationship with cerebral malaria has been previously reported39. As avidity of IC binding to erythrocytes 
depends on CR1 clustering, clearance of ICs could potentially vary with different CR1 clustering patterns.
We therefore set up a study using blood samples from healthy children in Kilifi, Kenya to examine the hypoth-
esis that the Sl2 and McCb polymorphisms might influence erythrocyte CR1 clustering.
Results
Erythrocyte CR1 clustering was assessed in blood samples from 125 Kenyan children with the homozygous 
Knops genotypes Sl1/Sl1 McCa/McCa, Sl2/Sl2 McCa/McCa or Sl2/Sl2 McCb/McCb. These genotypes are hereafter 
referred to as 1a, 2a and 2b respectively. Only homozygous genotypes were studied in order to examine the 
associations of the “pure forms” of the polymorphisms on CR1 clustering. The characteristics of the children are 
Figure 1. Diagram of the most common CR1 size variant (CR1*1). Adapted from Schmidt et al.70. The 
extracellular domain of CR1 is composed of 30 Complement Control Protein (CCP) domains organized into 
four “Long Homologous Repeats” (LHR). Two major functional sites are found within the CR1 molecule. Site 1 
is located in LHR-A (CCP 1–3) and is the binding site for C4b and the Plasmodium falciparum invasion ligand 
PfRh4, and has decay accelerating activity. Site 2 is located in LHR-B (CCP 8–10) and LHR-C (CCP 15–17), and 
binds C3b and C4b, and interacts with P. falciparum infected erythrocytes to form rosettes. In addition, site 2 
has Factor I-cofactor activity. SNPs determining the Sl and McC polymorphisms are localized in LHR-D (CCP 
25, shown in red). CCP regions within Sites 1 and 2 that share high sequence identity (between 1 to 3 amino 
acid changes) are represented with identical shading. TM, transmembrane region; CYT, cytoplasmic tail.
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summarised in Table 1; no significant differences were seen between the 1a, 2a or 2b genotype groups in terms of 
gender, age, ABO blood group, α+thalassaemia genotype or sickle cell genotype.
In order to examine CR1 clusters, we carried out immunofluorescent staining of unfixed erythrocytes with a 
monoclonal antibody to CR1 (Fig. 2A), and analysed confocal microscopy images with an automated protocol 
developed using Volocity Image Analysis software (version 6.3, Perkin Elmer) to determine CR1 erythrocyte 
cluster number and volume (Fig. 2B–H and Supplementary Videos 1 and 2).
Increased CR1 copy number in individuals with the McCb/McCb genotype. CR1 copy number 
(mean number of CR1 molecules per erythrocyte) positively correlates with number of CR1 clusters25,32,33 and was 
therefore measured in all individuals. We first examined the association of CR1 copy number and donor variables 
in univariate analyses. We observed that individuals with the 2b genotype showed a trend towards  higher CR1 
copy number than individuals with 1a and 2a genotypes (Table 1 and Fig. 3A, p = 0.098 by ANOVA). This was 
driven by the McC component of the genotype, as individuals with the McCb/McCb genotype had a significantly 
higher CR1 copy number than McCa/McCa (mean 658 copies per cell versus 483 copies per cell, p = 0.033, t-test, 
Fig. 3B). The Sl component of the genotype was not significantly associated with CR1 copy number (p = 0.978, 
t-test, Fig. 3C). Age, gender, ABO blood group and sickle cell trait showed no significant association with CR1 
copy number in this study. Individuals who were homozygotes for α+thalassaemia had a lower CR1 copy number 
(441) than those who were heterozygotes (495) or who had normal α globin (520), however this was not signifi-
cant (p = 0.366, ANOVA, Figure S1).
Increased CR1 cluster number in individuals with the McCb/McCb genotype. As previously 
reported26,29,32, the number of CR1 clusters per cell varied widely within each individual. Overall, the number 
of clusters per cell ranged from 0 to 43, with the maximum number of clusters per cell ranging from 15 to 43 
amongst different individuals (Figure S2). The volume of CR1 clusters also varied within individuals, with the 
largest clusters being > 3μm3 (Figure S3).
Preliminary analysis of the relationship between Knops genotype and erythrocyte CR1 cluster number was 
conducted by ANOVA, with data summarised at the level of the individual donor (i.e. using a single data point 
per donor, representing the median cluster number for that donor). These data were suggestive of a higher cluster 
number in 2b individuals, driven by the McCb genotype, although this was not statistically significant (Fig. 3D–F). 
Similar analysis by ANOVA of the relationship between Knops genotype and mean CR1 cluster volume revealed 
no significant associations (Fig. 3G–I). There were also no significant associations between CR1 cluster number 
(Figure S4) or cluster volume (Figure S5) and age, gender, ABO blood group, sickle cell genotype and α+thalas-
saemia genotype.
In agreement with previous findings32,33, a strong positive linear correlation was observed between CR1 clus-
ter number and CR1 copy number (R2 = 0.530, p < 0.001, Fig. 4A), and a positive correlation was also observed 
between CR1 cluster volume and CR1 copy number (R2 = 0.398, p < 0.001, Fig. 4B). Cluster number and cluster 
Characteristic Total (n)
Genotype#
p value1a (n = 29) (%) 2a (n = 88) (%) 2b (n = 8) (%)
Gender
  Male 73 17 (59) 51 (58) 5 (62.5) 1*
  Female 52 12 (41) 37 (42) 3 (37.5)
Age (months)
  Mean (SD) NA 130 (34) 119 (32) 138 (36) 0.124§
ABO blood group
  O 68 16 (55) 47 (53) 5 (62.5) 0.930*
  A 29 8 (28) 19 (22) 2 (25)
  B 23 5 (17) 17 (19) 1 (12.5)
  AB 5 0 (0) 5 (6) 0 (0)
α+thalassaemia genotype‡
  αα/αα 49 12 (41) 33 (38) 4 (50) 0.857*
  −α/αα 51 13 (45) 35 (40) 3 (37.5)
  −α/−α 25 4 (14) 20 (22) 1 (12.5)
Sickle cell (HbS) genotype‡
  AA 108 25 (86) 77 (88) 6 (75) 0.547*
  AS 17 4 (14) 11 (12) 2 (25)
CR1 copy number
  Mean (SD) NA 495 (204) 478 (221) 658 (305) 0.098§
Table 1. Characteristics of individuals studied. #1a = Sl1/Sl1, McCa/McCa genotype, 2a = Sl2/Sl2, McCa/McCa 
genotype, 2b = Sl2/Sl2, McCb/McCb genotype. *Fisher’s exact test, §One-way ANOVA. ‡α+thalassaemia and 
sickle cell genotype were included in the study as both have previously been reported to influence CR1 copy 
number40,42,63. SD, standard deviation. NA, not applicable.
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Figure 2. Immunofluorescent staining of erythrocyte CR1 clusters and image analysis. (A) Erythrocyte CR1 clusters 
were visualised by staining with 5 μg/ml of CR1 monoclonal antibody J3D3, followed by 4 μg/ml of Alexa Fluor 
488 goat anti-mouse IgG. See methods for full details. (B) For each donor, five confocal microscopy images were 
taken from the central area of the microscope slide as indicated by the grey shaded areas. Each image was a Z-stack 
comprising 8–10 steps. (C–F) To illustrate the image analysis process, a section containing 4 erythrocytes from one 
of the 5 images from a single donor is shown. Overall, at least 200 erythrocytes were examined per donor. (C) For 
each image, the bright-field view was used to identify the positions of erythrocytes. (D) Non-touching cells were then 
stamped. (E) The stamped region was then applied to the fluorescent image. (F) Cluster numbers and volumes within 
the stamped regions were assessed by an automated protocol using Volocity software as described in the methods. (G) 
An example of the clusters identified in a single erythrocyte. (H) The same erythrocyte as shown in G, with distinct 
clusters being shown in different colours. (I) A different erythrocyte with each of the 8 steps that comprise the Z-stack 
shown separately (1 to 8). These images can also be viewed as a video (Supplementary Videos 1 and 2).
www.nature.com/scientificreports/
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volume were also strongly positively correlated (R2 = 0.573, p < 0.001, Fig. 4C). Because of the potential con-
founding effect of CR1 copy number on the relationship between Knops genotype and CR1 cluster number and 
volume, more detailed statistical analyses were carried out.
No evidence of an association between Knops genotype and CR1 cluster number after adjust-
ment for CR1 copy number. A hierarchical mixed effects Poisson regression analysis was constructed to 
include all available data at the level of the cell (using at least 200 data points per individual donor, representing 
the CR1 cluster number for each cell imaged) and to allow for adjustment for CR1 copy number. The analysis 
examined each donor variable (combined Sl and McC genotype, Sl genotype alone, McC genotype alone, gender, 
age, ABO blood group, α+thalassaemia genotype or sickle cell genotype) in turn. Each donor variable was spec-
ified as a fixed effect and donor identifier and date of assay were specified as random effects. The relationship 
between each donor variable and the number of CR1 clusters per cell was reviewed both before and after adjust-
ment for CR1 copy number.
Prior to inclusion of CR1 copy number in the model, the 2b genotype was associated with a higher number of 
clusters per cell than the 1a genotype (multiplicative increase of 1.200 (95% CI 0.997–1.443, p = 0.053, Table 2)). 
When broken down by component genotypes, this association was driven by the McC component rather that 
Figure 3. The McCb genotype is associated with increased CR1 copy number and cluster number. Preliminary 
exploration of the association of Swain Langley (Sl) and McCoy (McC) genotypes with CR1 copy number (mean 
number of CR1 molecules per erythrocyte), median CR1 cluster number per cell and mean cluster volume. 
Panels (A–C) Relationship between CR1 copy number and (A) combined Sl and McC genotype (1a = Sl1/Sl1 
McCa/McCa, 2a = Sl2/Sl2 McCa/McCa and 2b = Sl2/Sl2 McCb/McCb), (B) McC genotype and (C) Sl genotype. 
Panels (D–F) Relationship between median number of CR1 clusters per cell and (D) combined Sl and McC 
genotype, (E) McC genoype and (F) Sl genotype. Panels (G–I) Relationship between mean CR1 cluster volume 
per cell and (G) combined Sl and McC genotype, (H) McC genoype and (I) Sl genotype. Red bars indicate mean 
and standard deviation, with statistical testing by t test or ANOVA as indicated. Individuals with the McCb 
genotype had significantly higher CR1 copy numbers than McCa individuals, and showed a trend towards 
higher CR1 cluster numbers, although this was not statistically significant.
www.nature.com/scientificreports/
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the Sl component, with the McCb/McCb genotype associated with a significantly higher number of clusters per 
cell than the McCa/McCa genotype (multiplicative increase = 1.216, 95% CI 1.027–1.439, p = 0.023, Table 2). 
No significant associations were seen for gender, age, ABO blood group, α+thalassaemia genotype or sickle cell 
genotype.
Figure 4. Positive correlation between CR1 copy number, cluster number and cluster volume. (A) Scatter plot 
of median CR1 cluster number per cell by CR1 copy number (mean number of CR1 molecules per cell) with 
linear regression. Each dot represents an individual donor. (B) Scatter plot of mean CR1 cluster volume by CR1 
copy number with linear regression. Each dot represents an individual donor. (C) Scatter plot of mean CR1 
cluster volume by median CR1 cluster number with linear regression. Each dot represents an individual donor. 
There were significant positive correlations between all three variables studied.
www.nature.com/scientificreports/
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The correlation between erythrocyte CR1 copy number and number of clusters per cell was strong, with each 
increase in CR1 copy number of 100 being associated with a multiplicative increase in CR1 cluster number of 
1.084 (95% CI 1.067−1.101, p < 0.001). Adjustment for CR1 copy number obscured any association between 
cluster number and McC genotype (Table 2). This suggests that the original association was likely to be driven by 
a difference in CR1 copy number, rather than any unique effect of the McC genotype itself.
No evidence of an association between Knops genotype and erythrocyte CR1 cluster volume 
after adjustment for CR1 copy number. Similarly, a more detailed hierarchical mixed effects linear 
regression analysis was constructed to include all available data at the level of the individual clusters, and to allow 
for adjustment for CR1 copy number. Donor variables (combined Sl and McC genotype, Sl genotype alone, McC 
genotype alone, gender, age, ABO blood group, α+thalassaemia genotype or sickle cell genotype) were examined 
individually as fixed effects, while cell identifier and donor identifier were specified as random effects (Table 3). 
The relationship between each donor variable and CR1 cluster volume was reviewed both before and after adjust-
ment for CR1 copy number.
No donor variables were found to have a significant association with cluster volume before adjustment for 
CR1 copy number (i.e. t values were all <1.96 or >−1.96). The correlation between CR1 copy number and cluster 
volume was extremely strong, with each increase in CR1 copy number of 100 being associated with an absolute 
increase in CR1 cluster volume of 0.039 µm3 (t value 9.446, Table 3. Bootstrapped p value <0.001). Adjustment 
for CR1 copy number had no impact on the non-significant relationships between cluster volume and combined 
Sl and McC genotype, Sl genotype alone, McC genotype alone, gender, age, α+thalassaemia genotype or sickle cell 
genotype (Table 3). However, in models adjusting for CR1 copy number, the B blood group was associated with an 
absolute increase in cluster volume of 0.057 µm3 when compared to the reference O blood group (t value = 2.305, 
Table 3. Bootstrapped p value = 0.028).
Cluster number Without adjustment for CR1 copy number With adjustment for CR1 copy number
Variable Median IQR Rate Ratio 95% CI p value Rate Ratio 95% CI p value
Combined Sl/McC genotype#
  1a 8 7–9 Reference NA NA Reference NA NA
  2a 8 7–10 0.982 0.888–1.085 0.717 0.992 0.920–1.069 0.831
  2b 9 9–11.5 1.200 0.997–1.443 0.053 1.043 0.906–1.201 0.557
Swain-Langley component alone
  Sl1/Sl1 8 7–9 Reference NA NA Reference NA NA
  Sl2/Sl2 8 7–10 1.000 0.904–1.106 0.998 0.997 0.925–1.073 0.926
McCoy component alone
  McCa/McCa 8 7–10 Reference NA NA Reference NA NA
  McCb/McCb 9 9–10.5 1.216 1.027–1.439 0.023 1.049 0.921–1.195 0.470
Gender
  Female 8 7–10 Reference NA NA Reference NA NA
  Male 8 6–10 0.970 0.891–1.056 0.488 1.014 0.952–1.081 0.669
ABO blood group
  O 8 7–10.25 Reference NA NA Reference NA NA
  A 8 7–9 1.030 0.926–1.146 0.587 1.044 0.966–1.129 0.277
  B 8 6–10.5 0.970 0.864–1.089 0.604 1.019 0.936–1.109 0.669
  AB 8 8–10 0.979 0.784–1.222 0.851 1.053 0.895–1.241 0.532
α+thalassaemia genotype
  αα/αα 9 7–11 Reference NA NA Reference NA NA
  −α/αα 8 7–9 0.934 0.846–1.031 0.176 0.982 0.911–1.058 0.631
  −α/−α 8 6–10 0.926 0.824–1.040 0.194 1.011 0.926–1.104 0.808
Sickle cell (HbS) genotype
  AA 8 7–10 Reference NA NA Reference NA NA
  AS 8 7–9 0.965 0.855–1.089 0.562 0.989 0.904–1.081 0.800
Age (years) Change in CR1 cluster number 
with each additional year of age 1.006 0.991–1.021 0.461 1.001 0.990–1.013 0.822
CR1 copy number Change in CR1 cluster 
number with each additional 100 CR1 copies 
per cell
NA NA NA 1.084 1.067–1.101 <0.001
Table 2. Effect of donor variables on cluster number from mixed effects Poisson regression. The rate ratio is the 
multiplicative change from the reference group. #1a = Sl1/Sl1, McCa/McCa genotype, 2a = Sl2/Sl2, McCa/McCa 
genotype, 2b = Sl2/Sl2, McCb/McCb. IQR = inter-quartile range, CI = confidence interval by Wald. NA, not 
applicable.
www.nature.com/scientificreports/
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Discussion
In agreement with existing literature, we report that both the number of CR1 clusters per erythrocyte and CR1 
cluster volume are highly correlated with an individual’s erythrocyte CR1 copy number25,32,33. The strength of 
association between CR1 copy number and cluster number was such that the inclusion of CR1 copy number in 
the statistical model obscured any other associations. However, on review of individual explanatory variables 
(without CR1 copy number in the model), the McCb/McCb genotype was associated with significantly higher 
cluster number than the McCa/McCa genotype. Individuals of the McCb/McCb genotype were found to have a 
significantly higher CR1 copy number than McCa/McCa, which is in agreement with a larger analysis of Kenyan 
children40. As such, it is likely that the association of the McCb/McCb genotype with increased CR1 cluster number 
was due to the higher CR1 copy numbers in McCb/McCb individuals, rather than being a distinct biological effect 
of the variant itself. Exactly how the McCb polymorphism influences erythrocyte CR1 copy number is unknown, 
but could be due to resistance to cleavage by tryptic proteases resulting from the lysine to glutamic acid (K1590E) 
mutation, as discussed previously40.
In contrast to existing literature40,41, we found no evidence of an association between donor age and CR1 copy 
number. However, the previous studies included children between birth and 13 years40 or birth and 32 years41, 
with the major changes occurring during the first four years of life. The narrower age range of our study (5.7 years 
–12.7 years) may explain why no association between age and CR1 copy number was detected. We also found 
no significant effect of α+thalassaemia genotype on CR1 copy number, unlike other studies which showed lower 
CR1 copy number in α+thalassaemia homozygotes compared to normal individuals in Papua New Guinea42 and 
Kenya40. Whilst we also observed a lower CR1 copy number in α+thalassaemia homozygote individuals, the small 
sample size in our study may have prevented this from reaching statistical significance.
One unexpected finding from this study was that blood group B was associated with significantly larger CR1 
clusters than the reference blood group O. There is no known link between ABO blood group and CR1 function, 
and further work will be required to determine if this is a reproducible finding, and if so, to determine its biolog-
ical significance.
Owing to the high level of within and between donor variation, this was a challenging assay to develop and 
interpret. The sample size of this study was small, in particular for the 2b genotype, which is a limitation of this 
Variable
Mean cluster 
volume (µm3) SD
Without adjustment for CR1 copy number With adjustment for CR1 copy number
Coefficient Standard error t value Coefficient Standard error t value
Combined genotype#
  1a 0.468 0.146 Reference NA NA Reference NA NA
  2a 0.476 0.127 0.012 0.029 0.400 0.016 0.022 0.717
  2b 0.502 0.160 0.035 0.054 0.658 −0.029 0.042 −0.708
Sl component alone
  Sl1/Sl1 0.468 0.146 Reference NA NA Reference NA NA
  Sl2/Sl2 0.478 0.130 0.014 0.029 0.475 0.012 0.022 0.552
McC component alone
  McCa/McCa 0.474 0.131 Reference NA NA Reference NA NA
  McCb/McCb 0.502 0.160 0.027 0.049 0.545 −0.041 0.038 −1.08
Gender
  Female 0.486 0.126 Reference NA NA Reference NA NA
  Male 0.468 0.137 −0.022 0.024 −0.895 −0.011 0.019 −0.584
ABO blood group
  O 0.469 0.137 Reference NA NA Reference NA NA
  A 0.476 0.100 0.008 0.030 0.264 0.029 0.023 1.275
  B 0.502 0.164 0.032 0.033 0.994 0.057 0.025 2.305
  AB 0.451 0.083 −0.022 0.063 −0.355 0.012 0.047 0.262
α+thalassaemia genotype
  αα/αα 0.493 0.139 Reference NA NA Reference NA NA
  −α/αα 0.475 0.136 −0.022 0.027 −0.805 −0.008 0.021 −0.401
  −α/−α 0.444 0.109 −0.051 0.033 −1.54 −0.017 0.026 −0.654
Sickle cell (HbS) genotype
  AA 0.472 0.133 Reference NA NA Reference NA NA
  AS 0.500 0.133 0.031 0.035 0.880 0.029 0.027 1.089
Age (years) Change in cluster volume with each 
additional year of age −0.002 0.004 −0.560 −0.005 0.003 −1.411
CR1 copy number Change in cluster volume 
with each additional 100 CR1 copies per cell NA NA NA 0.039 0.004 9.446
Table 3. Effect of donor variables on cluster volume from mixed effects linear regression. The coefficient is 
the absolute change from the reference group. #1a = Sl1/Sl1, McCa/McCa genotype, 2a = Sl2/Sl2, McCa/McCa 
genotype, 2b = Sl2/Sl2, McCb/McCb. SD, standard deviation. NA, not applicable.
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study. However, given the logistics of sampling (see methods), it was not possible to recruit more individuals pro-
spectively. Another consideration is that although all children positive for malaria on a thick film were excluded, 
information on other infective or inflammatory conditions that might influence CR1 copy number was not avail-
able. Therefore, it is possible that the CR1 copy number of some children may have been transiently altered by 
concurrent conditions. However, all children were sampled in the community and were not inpatients in health 
centres, therefore were in broadly good health.
The use of field samples also conferred other limitations on our study. When carrying out the confocal imag-
ing in Edinburgh, we used conservative imaging settings to avoid photo-bleaching the slides during image 
acquisition. This was done in case repeated imaging was needed, as the slides themselves could not be replaced. 
Therefore, it is possible that we may have under-sampled the immunofluorescent slides, resulting in missing very 
small clusters. As temperature has been reported to affect cluster size in some studies43, the use of physiological 
temperature during the assay (rather than 4 °C as used here) may have increased the relevance of the findings, 
as may the use of a physiological ligand to induce clustering (e.g. C3b covered beads or immune complexes). 
Furthermore, the J3D3 monoclonal antibody used here recognises multiple epitopes in LHRs A, B and C44, and 
results could therefore be influenced by CR1 size polymorphisms (allotype), which was not accounted for here. 
An antibody with a single epitope on CR1 that would not be affected by CR1 allotype43 could be used in future 
studies. Other technical aspects of the assay may have affected the results shown here. For example, the mounting 
medium used after staining and preparing the thin blood films can cause lysis of the erythrocytes, potentially 
bringing the top and bottom membranes closer together. This could cause overlap of some clusters making them 
appear fewer or larger than in vivo. Despite these limitations, our methods were consistent throughout all sam-
ples, thus allowing for direct comparison between the different genotypes.
The functional effects of the Sl and McC polymorphisms remain elusive. Laboratory evidence suggests that Sl2 
may affect rosetting (the binding of Plasmodium falciparum infected erythrocytes to uninfected erythrocytes)19, 
a parasite virulence factor associated with severe malaria in African children45. Rosetting occurs when P. falci-
parum Erythrocyte Membrane Protein 1 (PfEMP1) expressed on the surface of infected erythrocytes binds to 
uninfected erythrocyte receptors, and is thought to involve site 2 on CR1 (the C3b binding site) in LHR-B and 
LHR-C46. Erythrocytes from Sl2/Sl2 donors rosette less well than erythrocytes from Sl1/Sl1 donors when PfEMP1 
is expressed heterologously on the surface of COS-7 cells19. However, a study using short recombinant proteins 
of the Sl and McC variants found no difference in their abilities to disrupt rosettes17. Further investigation of the 
effects of the Knops polymorphisms on P. falciparum rosetting is required.
In addition to its role in rosetting, CR1 has also been identified as a sialic acid-independent invasion recep-
tor for P. falciparum47, via the reticulocyte-binding–like homolog 4 (PfRh4)48. The binding of PfRh4 has been 
mapped to site 1 in LHR-A49–51. Immuno-fluorescent staining of freshly released invasive merozoites showed 
CR1 on erythrocytes to be more intense around the merozoite, referred to by the authors as “capping,” suggest-
ing CR1 clustering may have a role in invasion47. However, the previously cited study using short recombinant 
proteins of the Sl and McC variants also found no difference in their abilities to inhibit erythrocyte invasion by P. 
falciparum17.
Interestingly, the binding site for mannose binding lectin (MBL) has been mapped to CCP 24–25, in close 
proximity to the Sl and McC polymorphisms52. MBL may influence malaria in Ghanaian children, with alleles 
responsible for low levels of MBL associated with increased parasite load, lower blood glucose levels and increased 
odds of severe malarial anaemia53,54. It has also been suggested that MBL may opsonize P. falciparum infected 
erythrocytes53 or merozoites55. However, whether the Sl or McC polymorphisms have functional effects on MBL 
interactions with CR1 has not yet been explored.
In summary, after accounting for the effect of CR1 copy number, there was no significant association between 
Sl or McC genotypes (separately or in combination) and erythrocyte CR1 cluster number or cluster volume in 
Kenyan children. The effects of the Sl and McC Knops blood group polymorphisms on CR1 function remain 
unknown.
Materials and Methods
Study Population and Ethical Approval. The Immunology Cohort Study Group in Kilifi, Kenya com-
prises 1041 children resident in the Junju or Ngerenya regions of the Kilifi Demographic Surveillance System 
(KDSS)56,57. The Kilifi district borders the Indian Ocean and the local economy depends on subsistence farm-
ing57. It is a malaria endemic area with seasonal transmission after the long (April -June) and short (October-
November) rainy seasons, although recently malaria transmission has fallen in the area58. Ethical approval for this 
study was obtained from the KEMRI Ethical Review Committee and all methods were performed in accordance 
with the relevant guidelines and regulations. Following informed consent from a parent or guardian, blood sam-
ples were obtained by venepuncture between 2nd and 30th April 2013 (inclusive).
Donor selection and genotyping. Donors had previously been genotyped for Sl and McC polymorphisms 
using the SEQUENOM iPLEX® Gold platform59, for sickle cell (HbS) and α+thalassaemia genotype (–α3.7 dele-
tion) by PCR60,61 and typed for ABO blood group by standard haemagglutination methods62. Our investigation 
was limited to the Sl and McC homozygote genotypes, 1a (Sl1/Sl1 McCa/McCa), 2a (Sl2/Sl2 McCa/McCa) and 2b 
(Sl2/Sl2 McCb/McCb). The 1b genotype does not occur because the McCb polymorphism is only found on the 
background of the Sl2 variant16,18. 148 children in the cohort with 1a, 2a or 2b genotypes, and with complete 
data on α+thalassaemia and sickle cell status (both reported to influence CR1 copy number40,42,63) were eligible 
for inclusion. Nine children did not attend for venepuncture, 12 were excluded because they were positive for P. 
falciparum on thick blood smear, and two were accidently discarded, giving 125 samples for analysis (29 with 
genotype 1a, 88 with genotype 2a and eight with genotype 2b).
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Sample collection and processing. 4.4 mls of venous blood was collected into a lithium heparin tube, 
centrifuged at 400 g for 10 minutes and plasma removed. The sample was then made up to 5 mls with R2 
medium (500 ml RPMI (catalogue number R0883, Sigma-Aldrich, Missouri, USA) with final concentration of 
0.02 M Hepes (Gibco, New York, USA), 0.1 mM L-glutamine (Gibco, New York, USA), 1% vol/vol Penicillin–
Streptomycin Solution Hybri-Max (Sigma-Aldrich, Missouri, USA) and 2% pooled human AB serum). The cell 
suspension was layered onto 3 ml of Lymphoprep (PROGEN Biotechnik, Heidelberg, Germany) and centrifuged 
at 1000 g for 20 minutes at 20 °C. The white cell layer was removed and the resulting erythrocytes washed twice in 
R2 medium without serum by centrifugation at 400 g for 5 minutes. They were then adjusted to 4% haematocrit 
by adding R2 medium without serum. The clustering assay was subsequently performed on these unfixed cells. 
As storage of blood samples can affect CR1 copy number and function43,64,65, all clustering assays were performed 
within eight hours of venepuncture.
CR1 copy number determination. An aliquot of washed erythrocytes from above was fixed in 5% for-
maldehyde (Sigma-Aldrich, Missouri, USA) on the day of venepuncture and CR1 copy number was determined 
within 8 weeks as previously described in detail65. Briefly, this method uses flow cytometry to quantify CR1 copy 
number on fixed erythrocytes using a standard curve derived from donors with known CR1 copy numbers that 
have been fixed at the same time as the samples. Erythrocytes were stained with 0.5 μg/ml J3D3 anti-CR1 mono-
clonal antibody (GTX44217, GeneTex, California, USA), followed by 5 μg/ml of Alexa Fluor 488-conjugated goat 
anti-mouse IgG (A-11001, ThermoFisher Scientific, Paisley, UK) and the mean fluorescence intensity determined 
on a FC500 flow cytometer (Beckman-Coulter Inc.). Examples of the gating strategy and staining of low, interme-
diate and high CR1 standard donors are shown in Figure S6.
Immunofluorescent staining of CR1 clusters. The IgG1 mouse anti-CR1 monoclonal antibody J3D3 was used 
to stain CR1 clusters, as it does not recognise epitopes in the LHR-D region44, so was considered unlikely to influence 
any effect the Sl or McC polymorphisms might have on clustering. Two aliquots from each sample of washed, unfixed 
erythrocytes at 4% haematocrit in PBS/1% BSA were incubated with 5 μg/ml of either J3D3 or IgG1 mouse anti-human 
isotype control (MCA928, AbD Serotec, Kidlington, UK) to give a final sample volume of 50 μl. Samples were incu-
bated at 4 °C for one hour (resuspended every ten mins) and washed three times in 1 ml cold PBS (Oxoid, Basingstoke, 
UK). 50 μl of 4 μg/ml Alexa Fluor 488-conjugated goat anti-mouse secondary antibody was added and the sample was 
incubated at 4 °C in the dark for one hour (resuspended every ten mins) and subsequently washed three times in 1 ml 
cold PBS. The sample was resuspended at 30–40% haematocrit, smeared on a glass slide, air-dried, mounted under a 
22 mm × 22 mm glass coverslip with 10 μl of DABCO-glycerol (2.5 mg DABCO (Sigma-Aldrich, Poole, UK), 0.5 ml 
glycerol and 0.5 ml PBS) and sealed with nail varnish. All steps to this point were undertaken at the KEMRI-Wellcome 
Trust Research Unit, Kilifi and the resultant slides were shipped to Edinburgh for confocal microscopy.
Confocal microscopy. Slides were imaged with a Leica SP5 confocal microscope using the glycerol × 63 objec-
tive, argon laser and differential interference contrast settings (now referred to as “bright field”). Five images per slide 
(Fig. 2A shows a representative image) were taken from predefined areas (Fig. 2B). To prevent bias for stained cells, each 
slide was navigated using the bright field image, ensuring that only erythrocyte outlines, rather than CR1 clusters, were 
visible. To minimise photo-bleaching, a Z-stack of images was taken at 0.8 μm intervals and between eight to ten steps 
were acquired per stack (an example of the 8 steps comprising a Z-stack are shown in Fig. 2I and Supplementary Videos 
1 and 2). The images in theZ-stack were then merged into one 3D image using Volocity 3D Image Analysis Software 
version 6.3 (PerkinElmer, Massachusetts, USA). Slides were imaged blind to donor information.
Image Analysis. Using the bright field image (to obscure CR1 clusters and increase objectivity) (Fig. 2C), a 
region of interest stamp 9 µm in diameter (area 63.6 µm2, slightly larger than an erythrocyte) was used to iden-
tify individual erythrocytes that were not touching other cells (Fig. 2D). Approximately 40 erythrocytes per 
image were stamped. Image analysis was then carried out within the stamped areas in the fluorescent channel 
(Fig. 2E,F). An automated software protocol was developed using the “Find objects” task in the “Measurements” 
module in Volocity version 6.3 (Perkin Elmer), and was used to determine the number of CR1 clusters per eryth-
rocyte (Fig. 2G,H), and to calculate the volume of each cluster. The protocol identified objects within the stamped 
area based on a minimum size threshold and subsequently separated touching objects using an object size guide. 
To establish the protocol settings, five cells from five separate donors (total cell number = 25) were reviewed. 
Settings over a range from 0.01 to 2.56 μm3 were examined for both minimum size and object size guide. A min-
imum size threshold of 0.06 μm3 and object size guide of 0.06 μm3 gave the optimal correlation with number of 
clusters identified by eye (Pearson’s correlation coefficient of 0.927 and r2 of 0.859), therefore these settings were 
used throughout. To account for background fluorescence, 30 maximum fluorescent intensity (MFI) readings 
were taken from areas of cells without visible CR1 clusters for each donor. The median of these readings was 
calculated for each individual to give the background MFI. The median of all donor medians was then calculated, 
giving a universal background correction factor (median = 554, IQR = 554–693) that was subtracted from all 
samples before running the Volocity protocol.
In order to determine the optimal number of cells to image from each donor, 400 erythrocytes were imaged 
from a single donor. The standard error of the mean (SEM) of the number of CR1 clusters per erythrocyte was 
plotted against the number of erythrocytes imaged (Figure S7). It was decided to image 200 erythrocytes for each 
donor, as gains in SEM beyond this point were small.
The reproducibility of the assay was assessed by imaging a blood sample taken from a single donor at the same 
time each day for three consecutive days. Neither the median number of CR1 clusters per cell, nor the mean CR1 
cluster volume was significantly different across the three days (Kruskal-Wallis test p = 0.337 and 0.054 respec-
tively) (Figure S8).
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Statistical analyses. Our experiments generated data on individual CR1 clusters from at least 200 eryth-
rocytes per donor. These data were then summarised at three levels: (1) at the level of each individual cluster (to 
allow for detailed analysis of cluster volume); (2) at the level of each individual cell (to allow for detailed analyses 
of cluster number per cell) and (3) at the level of each individual donor (to provide a single data point for each 
participant which represented their median CR1 cluster number or mean cluster volume).
Initial exploratory analyses used the data at the level of the individual donor to examine the influence of donor 
variables on CR1 copy number, CR1 cluster number and cluster volume. The donor variables explored in our 
analyses were basic demographic data (age and gender), other variables reported to influence CR1 copy number 
(α+thalassaemia genotype and sickle cell genotype)40,42,63, ABO blood group (repeatedly associated with malaria 
in this population)59,62 and Knops genotype (1a, 2a and 2b). Correlation between continuous variables was ana-
lysed by linear regression, and differences between means were analysed by one-way ANOVA or unpaired t tests.
To examine factors potentially influencing CR1 cluster number, the data were then analysed at the level of the 
individual cells. To permit inclusion of all the data collected and account for the intra-donor individual variation 
in the number of clusters per cell, a two-level hierarchical mixed effects Poisson regression model was used. 
Donor identifier and date the experiment was performed were included as random effects. Each donor variable 
(as above) was then examined in turn as a fixed effect. In view of the well documented relationship between CR1 
cluster number and CR1 copy number25,32,33, each variable was examined both with and without CR1 copy num-
ber in the model.
Finally, to examine factors potentially influencing CR1 cluster volume and account for both intra-individual 
and intra-cell variation in volume of clusters, a three-level hierarchical mixed effects linear regression model 
was used with both donor identifier and cell identifier included as random effects. Each donor variable was then 
examined as a fixed effect with and without CR1 copy number in the model. Where t values were significant, 
bootstrapping with 1000 iterations was performed to provide an equivalent p value for ease of interpretation.
Analyses were performed using R statistical software (R Foundation for Statistical Computing, Vienna, 
Austria)66 using the packages “plyr”, “ggplot2”, “boot” and “lme4”67–69. Graphs were drawn using GraphPad Prism 
7 (GraphPad Software, Inc., La Jolla, CA, USA).
Data availability. Data at the level of individual donors are in Supplementary dataset 1, data at the level of 
individual cells are in Supplementary dataset 2, and data at the level of individual clusters are in Supplementary 
dataset 3.
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